The Impact: Billion Dollar Challenge
It began with two donation envelopes, totaling $5.18, from a young girl, Elle, whose grandfather had been treated at Princess Margaret Cancer Centre. Her heartfelt gift, on April 12, 2012, launched our Billion Dollar Challenge, the largest single fundraising campaign in the history of Canadian healthcare to support the creation and delivery of personalized cancer medicine.
The goal: To secure $500 million through philanthropy and another $500 million through research grants over 5 years.
In January 2013, Emmanuelle Gattuso and her husband, Allan Slaight, and the Slaight family, made a significant commitment with a historic donation of $50 million.
The following year, on October 15, 2014, The Princess Margaret Cancer Foundation announced several transformational investments. This included the largest-ever research expansion for The Princess Margaret and an unprecedented recruitment drive of 26 international cancer experts and their teams.
Then, another gift, made on behalf of nine of Canada’s leading gold mining companies. Six gold bars weighing a total of 2,400 troy ounces with a total value of more than $3.28 million. Agnico Eagle Mines Ltd., Barrick Gold Corporation, Goldcorp Inc., IAMGOLD, Kinross Gold Corporation, New Gold Inc., Primero Mining Corp., Silver Wheaton Corp. and Yamana Gold Inc. all contributed.
These generous donations, and the hundreds of thousands of others made over the past five years, have allowed the Cancer Centre to expand and streamline biobanks, establish the cancer genomics program, accelerate the Epigenetics Program, as well as amplify the Cancer Clinical Research Unit (CCRU) and expand our research enterprise to the Princess Margaret Cancer Research Tower. The full list of what we have built and what we have done is detailed below.
The success of our Billion Dollar Challenge would not have been possible without the support of our donors, participants, granting agencies, event and lottery participants, volunteers, program partners, sponsors and staff.
We are most grateful for the generous support of our community which totaled over 1,802,000 gifts and the purchase of over 3,000,000 mega lottery tickets over the past 5 years. Because of you, we are now in the early days of delivering on our promise of personalized cancer medicine. With your continued support, we will conquer cancer in our lifetime.
WHAT WE HAVE DONE
New Patient Programs in:
DISCOVERIES & ACCOMPLISHMENTS
Drs. Philippe Bedard and Lillian Siu: Launch the first stage of the Integrated Molecular Profiling in Advanced Cancer Trial (IMPACT) by basing treatment on the molecular profile of each patient's tumour. Read More>>
Dr. Michael Milosevic: Demonstrates low oxygen levels in tumours can be used to predict cancer recurrence in men with intermediate-risk prostate cancer even before they receive radiation therapy. Read More>>
Dr. John Dick: Identifies a way to follow single tumour cells and observe their growth over time.
Dr. Rodger Tiedemann: Discovers root cause of multiple myeloma relapse.
Dr. Vuk Stambolic: Reveals a new function for the PTEN tumour suppressor opening new possibilities for how PTEN-defective patient tumours can be treated.
Dr. John Dick: Uncovers a promising new approach to treating colorectal cancer by disarming the gene that drives self-renewal in stem cells that are the root cause of the disease. Read More>>
Dr. Gordon Keller: Identifies key regulator controlling formation of blood-forming stem cells.
Drs. Mona Gauthier & Tak Mak: Discover how BRCA1 mutation starts in breast and ovarian cancers.
Dr. Mathieu Lupien: Identifies the signalling pathway that is over-activated in estrogen receptor-positive breast cancer cells that are resistant to hormone therapies.
Dr. Brenda Gallie: Discovers a new type of retinoblastoma, a rapidly developing eye cancer that affects very young babies. Read More>>
Dr. Tak Mak: Identifies PLK4 as a new therapeutic target in cancer. A drug aimed at this target has been approved by Health Canada and is in clinical trial at The Princess Margaret. Read More>>
Dr. Robert Bristow: Develops a genetic test to identify which men are at a higher risk for their prostate cancer to come back after localized treatment with surgery or radiotherapy. Read More>>
Dr. Gary Rodin: Launches a new global institute in Toronto that will boost research on life-threatening disease and palliative care. Read More>>
Dr. John Dick: Identifies pre-leukemic, hematopoietic stem cells paving a new way for early detection and treatment of acute myeloid leukemia. Read More>>
Drs. John Cho and Dr. Marc de Perrot: Pioneer a treatment technique against mesothelioma which leads to an increased survival rate. Read More>>
Dr. John Cho: Reveals radiation before surgery more than doubles mesothelioma survival.
Dr. Camilla Zimmermann: Demonstrates earlier palliative care improves quality of life and patient satisfaction.
Dr. Daniel De Carvalho: Uncovers a new drug target and repositions it to induce viral mimicry in order to heighten immunotherapy.
Dr. Lillian Siu: Indicates that vaccinating 12-year-old boys against the human papillomavirus (HPV) may be a cost-effective strategy for preventing a cancer that affects the back of the throat and mouth. Read More>>
Drs. Fei-Fei Liu and Anthony Fyles: Reveal women with Luminal A subtype breast cancer – particularly those older than 60 – may not need radiation treatment if they are already taking hormone therapy. Read More>>
Dr. John Dick: Redefines how human blood is made.
Dr. Rama Khokha: Discovers that blocking the master regulator of bone renewal stops osteosarcoma.
Dr. David Hodgson: Reveals early MRI screening reduces breast cancer death for survivors of childhood Hodgkin’s lymphoma (HL). Read More>>
Dr. Jean Wang: Develops a test for leukemia patients that can predict at diagnosis if patients will respond to standard treatment. Read More>>
Dr. Hansen He: Pinpoints 45 genes associated with prostate cancer development and progression.
Dr. Thomas Kislinger: Identifies an innovative, non-invasive way to identify aggressive prostate cancer using liquid biopsy biomarkers. Read More>>
Dr. Daniel De Carvalho: Discovers three distinct subgroups of disease and identifies promising drugs to target each type. Read More>>
Dr. John Dick: Discovers the switch to harness the power of cord blood for cancer treatment. Read More>>
Dr. Geoffrey Liu: Identifies a marker that shows up in a blood test that determines which patients with colorectal cancer, which has spread, would benefit from receiving the drug cetuximab. Read More>>
• Dr. Anna Spreafico
• Dr. Chana Korenblum
• Dr. David Wiljer
• Dr. Dawn Maze
• Dr. Elena Elimova
• Dr. Frank Michelis
• Dr. Genevieve Bouchard
• Dr. Hassan Sibai
• Dr. Joelle Helou
• Dr. Pam Mosher
• Dr. Stephanie L’Heureux
• Dr. Faiyaz Notta
• Dr. Aaron Hansen
• Dr. Alejandro Berlin
• Dr. Auro Viswabandya
• Dr. Danielle Kain
• Dr. David Brooks
• Dr. David Shultz
• Dr. Eric Monteiro
• Dr. Jennifer Croke
• Dr. Jenny Lau
• Dr. Steven Chan
• Dr. Tracy McGaha
• Dr. Ahmed Al-Awamer
• Dr. Anca Prica
• Dr. David Cescon
• Dr. Douglas Chepeha
• Dr. Ken Aldape
• Dr. Kevin Kuo
• Dr. Penelope Bradbury
• Dr. Raymond Kim
• Dr. Scott Bratman
• Dr. Andrea Weiss
• Dr. Benjamin Haibe-Kains
• Dr. Breffni Hannon
• Dr. Daniel De Carvalho
• Dr. Kathy Han
• Dr. Katie Marchington
• Dr. Marcus Butler
• Dr. Michael Hoffman
• Dr. Michael Roehrl
• Dr. Naoto Hirano
• Dr. Neesha Dhani
• Dr. Raymond Jang
• Dr. Santhosh Thyagu
• Dr. Trevor Pugh
• Dr. Taymaa May
• Dr. Eitan Amir
• Dr. Meredith Giuliani
• Dr. Jennifer Jones